Immuneering (IMRX) Total Liabilities (2020 - 2024)
Historic Total Liabilities for Immuneering (IMRX) over the last 5 years, with Q3 2024 value amounting to $10.8 million.
- Immuneering's Total Liabilities rose 986.47% to $10.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $10.8 million, marking a year-over-year increase of 986.47%. This contributed to the annual value of $12.0 million for FY2023, which is 406.38% down from last year.
- Per Immuneering's latest filing, its Total Liabilities stood at $10.8 million for Q3 2024, which was up 986.47% from $10.8 million recorded in Q2 2024.
- In the past 5 years, Immuneering's Total Liabilities registered a high of $12.5 million during Q4 2022, and its lowest value of $2.8 million during Q4 2020.
- Moreover, its 5-year median value for Total Liabilities was $9.9 million (2023), whereas its average is $9.2 million.
- Its Total Liabilities has fluctuated over the past 5 years, first skyrocketed by 28294.13% in 2021, then tumbled by 1640.15% in 2023.
- Over the past 5 years, Immuneering's Total Liabilities (Quarter) stood at $2.8 million in 2020, then skyrocketed by 282.94% to $10.7 million in 2021, then rose by 16.71% to $12.5 million in 2022, then fell by 4.06% to $12.0 million in 2023, then dropped by 9.76% to $10.8 million in 2024.
- Its Total Liabilities was $10.8 million in Q3 2024, compared to $10.8 million in Q2 2024 and $9.3 million in Q1 2024.